Revenue and taxation; require vapor product manufacturers to disclose ingredients in consumable vapor products distributed, sold, or offered for sale
HB 958 would add a new section to Georgia’s tobacco and vaping tax laws requiring manufacturers of consumable vapor products sold, distributed, or offered for sale in the state to disclose product ingredients to the commissioner beginning no later than January 1, 2027, and then annually thereafter. The required submission includes a full ingredient list in descending order by weight, a description of research and investigations on human health effects, a list of ingredients identified as chemicals of concern, and an explanation of any evaluation of alternatives to those chemicals.
The bill also requires manufacturers to post ingredient lists on their websites in a public, machine-readable format, with updates whenever ingredients or their predominance changes. It defines “chemical of concern” broadly to include substances such as allergens, asthmagens, carcinogens, mutagens, endocrine disruptors, reproductive or developmental toxicants, persistent bioaccumulative toxicants, and neurotoxicants, and it allows the commissioner to identify additional chemicals or classes by rule. Proprietary processes or ingredients are exempt from disclosure if the commissioner determines they qualify, and violations would be treated as misdemeanors and could lead to probation, suspension, or revocation of the manufacturer’s state licenses.
The bill’s impact would be to create a new regulatory disclosure regime for vapor product manufacturers operating in Georgia, increasing transparency about e-cigarette and vaping product contents and potentially giving state regulators more information about health risks and product composition. It would also give the commissioner authority to adopt rules defining certain chemicals of concern and to determine the scope of exemptions for proprietary information, while tying compliance to licensing consequences under existing tobacco and vaping law.
There is no recorded committee transcript or vote history provided, so the overall sentiment cannot be measured from formal debate or roll call data. Based on the bill text alone, the measure appears oriented toward consumer protection, public health, and regulatory oversight rather than tax collection. Any opposition would likely center on confidentiality concerns, burdens on manufacturers, and the scope of the commissioner’s discretion, but those objections are not documented in the materials provided.
Notable points of contention in the bill itself include the breadth of the definition of “chemical of concern,” the requirement to disclose research and alternative evaluations, and the balance between transparency and protection of proprietary processes. The bill also gives the commissioner significant rulemaking authority, which could be a source of debate over how much discretion the agency should have in determining what must be disclosed and what may be exempted.
HB 958 would amend Chapter 11 of Title 48 of the Official Code of Georgia Annotated by adding a new disclosure and reporting requirement for vapor product manufacturers. It would require annual ingredient reporting to the commissioner, public website posting of ingredient lists, and compliance with machine-readable publication standards, while also authorizing penalties including misdemeanor treatment and possible license probation, suspension, or revocation for violations. The bill would affect manufacturers of consumable vapor products sold in Georgia and expand the commissioner’s regulatory authority over ingredient disclosure and exemptions.
No committee discussion or vote data is available, so there is no documented legislative sentiment from hearings or floor action. From the bill’s structure and purpose, the measure appears generally supportive of public health and consumer transparency, but it also imposes new compliance obligations on manufacturers. Any sentiment against the bill would likely come from industry concerns about confidentiality, administrative burden, and regulatory discretion, though those views are not reflected in the provided record.
The main likely points of contention are the scope of required disclosures, especially the broad definition of “chemical of concern,” and whether manufacturers should have to disclose research on health effects and alternative ingredients. Another likely issue is the exemption for proprietary processes or ingredients, which depends on commissioner determination and could be viewed as either necessary protection for trade secrets or an overly broad carveout. The bill’s enforcement provisions, including misdemeanor penalties and possible license suspension or revocation, may also be controversial among manufacturers and retailers.